Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib

A number of CML patients who achieve a sustained complete molecular response (CMR) for at least 2 years during imatinib (IM) therapy can discontinue IM without relapse. With the long‐term goal of developing immunological criteria for managing IM therapy in CML patients, we compared the immunophenoty...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Mizuguchi, Junichiro, Tauchi, Tetsuzo, Kimura, Yukihiko, Inokuchi, Koiti, Ohyashiki, Junko H., Ohyashiki, Kazuma
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2013
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656535/
https://ncbi.nlm.nih.gov/pubmed/23758044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12216
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares